Cristin-resultat-ID: 1300799
Sist endret: 2. februar 2016 14:41
NVI-rapporteringsår: 2015
Resultat
Vitenskapelig artikkel
2015

Rapid anti-inflammatory effects of gonadotropin-releasing hormone antagonism in rheumatoid arthritis patients with high gonadotropin levels in the Agra trial

Bidragsytere:
  • Anita Anjali Suri Kåss
  • Ivana Hollan
  • Morten Fagerland
  • Hans-Christian Gulseth
  • Peter A Torjesen og
  • Øystein Thorleiv Førre

Tidsskrift

PLOS ONE
ISSN 1932-6203
e-ISSN 1932-6203
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2015
Publisert online: 2015
Volum: 10:e013439
Hefte: 10
Open Access

Importkilder

Scopus-ID: 2-s2.0-84948783369

Beskrivelse Beskrivelse

Tittel

Rapid anti-inflammatory effects of gonadotropin-releasing hormone antagonism in rheumatoid arthritis patients with high gonadotropin levels in the Agra trial

Sammendrag

Abstract Objectives Gonadotropin-releasing hormone (GnRH) and pituitary gonadotropins, which appear to be proinflammatory, undergo profound secretory changes during events associated with rheumatoid arthritis (RA) onset, flares, or improvement e.g. menopausal transition, postpartum, or pregnancy. Potential anti-inflammatory effects of GnRH-antagonists may be most pronounced in patients with high GnRH and gonadotropin levels. Therefore, we investigated the efficacy and safety of a GnRH-antagonist, cetrorelix, in RA patients with high gonadotropin levels. Methods We report intention-to-treat post hoc analyses among patients with high gonadotropin levels (N = 53), i.e. gonadotropin levels>median, from our proof-of-concept, double-blind AGRA-study (N = 99). Patients with active longstanding RA, randomized to subcutaneous cetrorelix (5mg days1–2; 3mg days 3–5) or placebo, were followed through day 15. Only predefined primary and secondary endpoints were analyzed. Results The primary endpoint, Disease Activity Score of 28-joint counts with C-reactive protein (DAS28-CRP), improved with cetrorelix compared with placebo by day 5 (-1.0 vs. -0.4, P = 0∙010). By day 5, more patients on cetrorelix achieved at least a 20% improvement in the American College of Rheumatology scale (44% vs. 19%, P = 0.049), DAS28-CRP≤3.2 (24% vs. 0%, P = 0.012), and European League against Rheumatism ‘Good-responses’ (19% vs. 0%, P = 0.026). Tumor necrosis factor-α, interleukin-1β, interleukin-10, and CRP decreased with cetrorelix (P = 0.045, P = 0.034, P = 0.020 and P = 0.042 respectively) compared with placebo by day 15. Adverse event rates were similar between groups. Conclusions GnRH-antagonism produced rapid anti-inflammatory effects in RA patients with high gonadotropin levels. GnRH should be investigated further in RA. Trial Registration ClinicalTrials.gov NCT00667758

Bidragsytere

Anita Anjali Suri Kåss

  • Tilknyttet:
    Forfatter
    ved Betanien Hospital
  • Tilknyttet:
    Forfatter
    ved Klinikk for kreft, kirurgi og transplantasjon ved Universitetet i Oslo

Ivana Hollan

  • Tilknyttet:
    Forfatter
    ved Revmatismesykehuset AS

Morten Wang Fagerland

Bidragsyterens navn vises på dette resultatet som Morten Fagerland
  • Tilknyttet:
    Forfatter
    ved Biostatistikk, epidemiologi og helseøkonomi (OSS) ved Oslo universitetssykehus HF

Hans-Christian Gulseth

  • Tilknyttet:
    Forfatter
    ved Betanien Hospital

Peter A Torjesen

  • Tilknyttet:
    Forfatter
    ved Spesialisert endokrinologi, seksjon for ved Oslo universitetssykehus HF
1 - 5 av 6 | Neste | Siste »